These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10025821)

  • 21. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.
    Liu L; Ikonen S; Heikkinen T; Tapiola T; van Groen T; Tanila H
    Exp Neurol; 2002 Feb; 173(2):196-204. PubMed ID: 11822883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metrifonate.
    Lamb HM; Faulds D
    Drugs Aging; 1997 Dec; 11(6):490-6. PubMed ID: 9413706
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
    Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
    J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacology of metrifonate.
    Jann MW
    Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
    Schreiter Gasser U; Gasser T
    Fortschr Med Orig; 2001 Nov; 119(3-4):135-8. PubMed ID: 11789125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
    Piecoro LT; Wermeling DP; Schmitt FA; Ashford JW
    Pharmacotherapy; 1998; 18(5):1129-32. PubMed ID: 9758325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
    Crismon ML
    Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.
    Pohanka M; Jun D; Kuca K
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):680-3. PubMed ID: 18825528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of the elderly dementia patients].
    Takeda M; Shinosaki K; Nishikawa T; Tanaka T; Kudo T; Nakamura Y; Kashiwagi Y
    Nihon Ronen Igakkai Zasshi; 2000 Nov; 37(11):879-81. PubMed ID: 11193359
    [No Abstract]   [Full Text] [Related]  

  • 33. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
    Mega MS; Dinov ID; Lee L; O'Connor SM; Masterman DM; Wilen B; Mishkin F; Toga AW; Cummings JL
    J Neuropsychiatry Clin Neurosci; 2000; 12(2):209-18. PubMed ID: 11001599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
    Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
    Gélinas I; Gauthier S; Cyrus PA
    J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease.
    Disterhoft JF; Oh MM
    J Physiol Paris; 2006; 99(2-3):180-92. PubMed ID: 16458491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic approaches to Alzheimer's disease.
    Schneider LS
    J Clin Psychiatry; 1996; 57 Suppl 14():30-6. PubMed ID: 9024334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.